Human leucocyte antigen (HLA-DR) gene expression is reduced in sepsis and correlates with impaired TNFα response: A diagnostic tool for immunosuppression?

PLoS ONE

Volumn 12, Issue 8, 2017, Pages

  Winkler, Martin Sebastian ^a   Rissiek, Anne ^a   Priefler, Marion ^a   Schwedhelm, Edzard ^a   Robbe, Linda ^a   Bauer, Antonia ^a   Zahrte, Corinne ^a   Zoellner, Christian ^a   Kluge, Stefan ^a   Nierhaus, Axel ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CD14 ANTIGEN; CD16 ANTIGEN; COMPLEMENTARY DNA; HLA DR ANTIGEN; INTERLEUKIN 6; PROCALCITONIN; SINGLE STRANDED DNA; TUMOR NECROSIS FACTOR; BIOLOGICAL MARKER; LIPOPOLYSACCHARIDE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE SEVERITY; EX VIVO STUDY; FEMALE; GENE EXPRESSION; HUMAN; IMMUNE DEFICIENCY; INNATE IMMUNITY; MALE; MONOCYTE; POSTOPERATIVE INFLAMMATION; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SEPTIC SHOCK; CASE CONTROL STUDY; DRUG EFFECTS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; METABOLISM; MIDDLE AGED; SEPSIS;

AGED; BIOMARKERS; CASE-CONTROL STUDIES; FEMALE; HLA-DR ALPHA-CHAINS; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; MONOCYTES; PROSPECTIVE STUDIES; SEPSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85026769618     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0182427     Document Type: Article

References (31)

1. Deutschman CS, Tracey KJ. Sepsis: current dogma and new perspectives. Immunity. 2014; 40(4):463–75. https://doi.org/10.1016/j.immuni.2014.04.001 PMID: 24745331.
2. Hamers L, Kox M, Pickkers P. Sepsis-induced immunoparalysis: mechanisms, markers, and treatment options. Minerva anestesiologica. 2015; 81(4):426–39. PMID: 24878876.
3. Boomer JS, Green JM, Hotchkiss RS. The changing immune system in sepsis: Is individualized immuno-modulatory therapy the answer? Virulence. 2013; 5(1). Epub 2013/09/27. PMID: 24067565. https://doi.org/10.4161/viru.26516
4. Wiedermann CJ. Adjuvant treatment of sepsis: what is known? Medizinische Klinik, Intensivmedizin und Notfallmedizin. 2014; 109(8):583–90. https://doi.org/10.1007/s00063-014-0379-7 PMID: 25330980.
5. Hou T, Huang D, Zeng R, Ye Z, Zhang Y. Accuracy of serum interleukin (IL)-6 in sepsis diagnosis: a systematic review and meta-analysis. Int J Clin Exp Med. 2015; 8(9):15238–45. PMID: 26629009; PubMed Central PMCID: PMCPMC4658898.
6. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. The Lancet Infectious diseases. 2013; 13(3):260–8. https://doi.org/10.1016/S1473-3099(13)70001-X PMID: 23427891; PubMed Central PMCID: PMC3798159.
7. Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, Gregor J, et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. American journal of respiratory and critical care medicine. 2009; 180(7):640–8. https://doi.org/10.1164/rccm.200903-0363OC PMID: 19590022.
8. Nierhaus A, Montag B, Timmler N, Frings DP, Gutensohn K, Jung R, et al. Reversal of immunoparalysis by recombinant human granulocyte-macrophage colony-stimulating factor in patients with severe sepsis. Intensive care medicine. 2003; 29(4):646–51. https://doi.org/10.1007/s00134-003-1666-6 PMID: 12595977.
9. Monneret G, Venet F. Monocyte HLA-DR in sepsis: shall we stop following the flow? Crit Care. 2014; 18 (1):102. https://doi.org/10.1186/cc13179 PMID: 24393356; PubMed Central PMCID: PMCPMC4056426.
10. Cajander S, Tina E, Backman A, Magnuson A, Stralin K, Soderquist B, et al. Quantitative Real-Time Polymerase Chain Reaction Measurement of HLA-DRA Gene Expression in Whole Blood Is Highly Reproducible and Shows Changes That Reflect Dynamic Shifts in Monocyte Surface HLA-DR Expression during the Course of Sepsis. PloS one. 2016; 11(5):e0154690. https://doi.org/10.1371/journal.pone.0154690 PMID: 27144640; PubMed Central PMCID: PMCPMC4856385.
11. Heagy W, Nieman K, Hansen C, Cohen M, Danielson D, West MA. Lower levels of whole blood LPS-stimulated cytokine release are associated with poorer clinical outcomes in surgical ICU patients. Surgical infections. 2003; 4(2):171–80. https://doi.org/10.1089/109629603766956960 PMID: 12906717.
12. Ploder M, Pelinka L, Schmuckenschlager C, Wessner B, Ankersmit HJ, Fuerst W, et al. Lipopolysaccharide-induced tumor necrosis factor alpha production and not monocyte human leukocyte antigen-DR expression is correlated with survival in septic trauma patients. Shock. 2006; 25(2):129–34. https://doi.org/10.1097/01.shk.0000191379.62897.1d PMID: 16525350.
13. Payen D, Faivre V, Lukaszewicz AC, Villa F, Goldberg P. Expression of monocyte human leukocyte antigen-DR in relation with sepsis severity and plasma mediators. Minerva anestesiologica. 2009; 75 (9):484–93. PMID: 19644434.
14. Venet F, Tissot S, Debard AL, Faudot C, Crampe C, Pachot A, et al. Decreased monocyte human leukocyte antigen-DR expression after severe burn injury: Correlation with severity and secondary septic shock. Critical care medicine. 2007; 35(8):1910–7. https://doi.org/10.1097/01.CCM.0000275271.77350.B6 PMID: 17568330.
15. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA: the journal of the American Medical Association. 2016; 315(8):801–10. https://doi.org/10.1001/jama.2016.0287 PMID: 26903338.
16. Leentjens J, Kox M, Koch RM, Preijers F, Joosten LA, van der Hoeven JG, et al. Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study. American journal of respiratory and critical care medicine. 2012; 186(9):838–45. https://doi.org/10.1164/rccm. 201204-0645OC PMID: 22822024.
17. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25(4):402–8. Epub 2002/02/16. https://doi.org/10.1006/meth.2001.1262 PMID: 11846609.
18. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nature reviews Immunology. 2013; 13(12):862–74. https://doi.org/10.1038/nri3552 PMID: 24232462; PubMed Central PMCID: PMC4077177.
19. Shalova IN, Lim JY, Chittezhath M, Zinkernagel AS, Beasley F, Hernandez-Jimenez E, et al. Human monocytes undergo functional re-programming during sepsis mediated by hypoxia-inducible factor-1alpha. Immunity. 2015; 42(3):484–98. https://doi.org/10.1016/j.immuni.2015.02.001 PMID: 25746953.
20. van der Bruggen T, Nijenhuis S, van Raaij E, Verhoef J, van Asbeck BS. Lipopolysaccharide-induced tumor necrosis factor alpha production by human monocytes involves the raf-1/MEK1-MEK2/ERK1-ERK2 pathway. Infect Immun. 1999; 67(8):3824–9. PMID: 10417144; PubMed Central PMCID: PMCPMC96660.
21. Gogos CA, Drosou E, Bassaris HP, Skoutelis A. Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. The Journal of infectious diseases. 2000; 181(1):176–80. https://doi.org/10.1086/315214 PMID: 10608764.
22. Munoz C, Carlet J, Fitting C, Misset B, Bleriot JP, Cavaillon JM. Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest. 1991; 88(5):1747–54. https://doi.org/10.1172/ JCI115493 PMID: 1939659; PubMed Central PMCID: PMCPMC295719.
23. Ertel W, Kremer JP, Kenney J, Steckholzer U, Jarrar D, Trentz O, et al. Downregulation of proinflammatory cytokine release in whole blood from septic patients. Blood. 1995; 85(5):1341–7. PMID: 7858264.
24. Segre E, Fullerton JN. Stimulated Whole Blood Cytokine Release as a Biomarker of Immunosuppression in the Critically Ill: The Need for a Standardized Methodology. Shock. 2016; 45(5):490–4. https://doi.org/10.1097/SHK.0000000000000557 PMID: 27089173; PubMed Central PMCID: PMCPMC4836558.
25. Rigato O, Salomao R. Impaired production of interferon-gamma and tumor necrosis factor-alpha but not of interleukin 10 in whole blood of patients with sepsis. Shock. 2003; 19(2):113–6. PMID: 12578117.
26. Tang BM, McLean AS, Dawes IW, Huang SJ, Lin RC. Gene-expression profiling of peripheral blood mononuclear cells in sepsis. Critical care medicine. 2009; 37(3):882–8. https://doi.org/10.1097/CCM. 0b013e31819b52fd PMID: 19237892.
27. Medzhitov R, Janeway C Jr. Innate immunity. The New England journal of medicine. 2000; 343(5):338–44. https://doi.org/10.1056/NEJM200008033430506 PMID: 10922424.
28. Rimmele T, Payen D, Cantaluppi V, Marshall J, Gomez H, Gomez A, et al. Immune Cell Phenotype and Function in Sepsis. Shock. 2016; 45(3):282–91. https://doi.org/10.1097/SHK.0000000000000495 PMID: 26529661; PubMed Central PMCID: PMCPMC4752878.
29. Caille V, Chiche JD, Nciri N, Berton C, Gibot S, Boval B, et al. Histocompatibility leukocyte antigen-D related expression is specifically altered and predicts mortality in septic shock but not in other causes of shock. Shock. 2004; 22(6):521–6. PMID: 15545822.
30. Lukaszewicz AC, Grienay M, Resche-Rigon M, Pirracchio R, Faivre V, Boval B, et al. Monocytic HLA-DR expression in intensive care patients: interest for prognosis and secondary infection prediction. Critical care medicine. 2009; 37(10):2746–52. https://doi.org/10.1097/CCM.0b013e3181ab858a PMID: 19707128.
31. Drewry AM, Ablordeppey EA, Murray ET, Beiter ER, Walton AH, Hall MW, et al. Comparison of monocyte human leukocyte antigen-DR expression and stimulated tumor necrosis factor alpha production as outcome predictors in severe sepsis: a prospective observational study. Crit Care. 2016; 20(1):334. https://doi.org/10.1186/s13054-016-1505-0 PMID: 27760554; PubMed Central PMCID: PMCPMC5072304.